摘要
儿童急性髓系白血病(acutemyeloid leukemia,AML)是儿童时期发病率第二位的白血病,占儿童白血病总数的15%~20%[1],目前长期生存率为60%~70%[2-4]。异基因造血干细胞移植(allo-HSCT)作为巩固治疗,与大剂量阿糖胞苷/蒽环类药物一起在儿童AML治疗中发挥着主要作用。
作者
中华医学会血液学分会干细胞应用学组
中华医学会儿科学分会
黄晓军
吴德沛
王天有
张晓辉
程翼飞
郑胡镛
张乐萍
Stem Cell Application Group,Chinese Society of Hematology,Chinese Medical Association;Chinese Pediatric Society,Chinese Medical Association;Huang Xiaojun;Wu Depei;Wang Tianyou;Zhang Xiaohui(不详;Peking University People's Hospital,Peking University Institute of Hematology,National Clinical Research Center for Hematologic Disease,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation,Beijing 100044,China;Department of Hematology,the First Affiliated Hospital of Soochow University,Jiangsu Institute of Hematology,National Clinical Research Center for Hematologic Disease,Suzhou 215006,China;Hematology Center,Beijing Children's Hospital,Capital Medical University,National Center for Children's Health,Beijing 100045,China)
出处
《中华血液学杂志》
CAS
CSCD
北大核心
2022年第10期802-809,共8页
Chinese Journal of Hematology
